Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tysabri in Crohn's Disease (CD FACTOR)
NCT00801125Phase 4Withdrawn
- Sponsor
- Biogen
- Start
- Dec 2008
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of natalizumab in Crohn's disease, sponsored by Biogen. Planned start Dec 2008; status: withdrawn.
02
Drugs
natalizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00801125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00801125.